Brief: Viracta Therapeutics Provides An Update On The Phase 1B/2 Trial Of Nana-Val In Patients With Advanced Epstein-Barr Virus-Positive (Ebv+) Solid Tumors And Announces Upcoming Poster Presentation At The Asco Annual Meeting

Viracta Therapeutics

02/06/2022 13:33

June 2 (Reuters) - Viracta Therapeutics Inc  VIRX.O :
    * VIRACTA THERAPEUTICS PROVIDES AN UPDATE ON THE PHASE 1B/2
TRIAL
OF NANA-VAL IN PATIENTS WITH ADVANCED EPSTEIN-BARR
VIRUS-POSITIVE (EBV+) SOLID TUMORS AND ANNOUNCES UPCOMING POSTER
PRESENTATION AT THE ASCO ANNUAL MEETING
    * VIRACTA THERAPEUTICS INC - TRIAL HAS ADVANCED TO SECOND
DOSE
ESCALATION COHORT WITH NO DOSE-LIMITING TOXICITIES OBSERVED
TO-DATE

Source text for Eikon:  ID:nPnbyzMmga 
Further company coverage:  VIRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))